Gene Wallenstein
Affiliations: | Pfizer R & D, Parsippany-Troy Hills, NJ, United States |
Area:
Neuroscience & ImmunologyGoogle:
"Gene Wallenstein"Mean distance: 13.76 (cluster 29) | S | N | B | C | P |
Parents
Sign in to add mentor| Steven L. Bressler | grad student | Pfizer R & D | |
| J. A.S. Kelso | grad student | Pfizer R & D | |
| Michael E. Hasselmo | post-doc | Pfizer R & D |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| van der Heijde D, Strand V, Tanaka Y, et al. (2019) Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study. Arthritis & Rheumatology (Hoboken, N.J.) |
| Olsen IC, Lie E, Vasilescu R, et al. (2018) Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology (Oxford, England) |
| Strand V, Mysler E, Moots RJ, et al. (2018) SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial Annals of the Rheumatic Diseases. 77: 990-991 |
| Bergrath E, Gerber RA, Gruben D, et al. (2017) Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. International Journal of Rheumatology. 2017: 8417249 |
| Schulze-Koops H, Strand V, Nduaka C, et al. (2017) Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford, England). 56: 46-57 |
| Strand V, Lee EB, Fleischmann R, et al. (2016) Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. Rmd Open. 2: e000308 |
| Claxton L, Jenks M, Taylor M, et al. (2016) An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of Managed Care & Specialty Pharmacy. 22: 1088-102 |
| Fleischmann R, Kremer J, Tanaka Y, et al. (2016) Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases |
| Strand V, van Vollenhoven RF, Lee EB, et al. (2016) Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford, England) |
| Bergrath E, Wallenstein G, Gerbert R, et al. (2016) SAT0165 Tofacitinib versus Biologic Treatments in Moderate To Severe Rheumatoid Arthritis Patients Who Have Had An Inadequate Response To Nonbiologic Dmards: Systematic Literature Review and Network Meta-Analysis Annals of the Rheumatic Diseases. 75: 726-726 |